Since 1999, Xi?痑n Hengtong Pharmaceuticals has made its bacteria strains part of the payloads aboard China?痵 Shenzhou series spacecraft for four consecutive times. Not long ago, it produced a Shenzhou III oral recipe using the raw strains mutated under the combined effects of microgravity, strong magnetic fields, heavy particles, strong radiation, and extremely high and low temperatures. Xi?痑n Hengtong has screened out a T33 strain after repeated segregation, culturing, screening, experiments, and trial productions. According to an examination report issued by the Institute of Microbiology, part of the Chinese Academy of Sciences, the strains have undergone some changes in morphological, culturing, physiological, and biochemical features. An analysis of their genetic properties and protein expressions show that the strains have been mutated genetically. Generation passing experiments confirmed the genetic stability of the strains, with fine adaptability for production. The new strains are featured with a noticeably accelerated growth, but a greatly shortened fermentation cycle. It produces a peptide content 30% higher than its mother strains.
Possessing 25 therapeutic effects and 22 patents, and offering an efficient, safe, toxicity free and hormone free treatment, the new oral recipe is the only space biomedicine produced by China, using space biotechnology, without chemical synthesis.
|
